Recent events
Recent events tied to this brand in public sources.
Back to profile49 entries · Page 1 of 3
2026
France recalls Tavneos batches after deaths linked in Japan
France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.
2024
Sandoz and Amgen settle US denosumab patent disputes
Sandoz announced an agreement with Amgen resolving patent disputes concerning Sandoz's FDA-approved denosumab biosimilars. The agreement permits Sandoz to enter the US market with biosimilar versions of Prolia and Xgeva on May 31, 2025, or earlier under specified circumstances.
2024
Amgen sues over state drug price cap
Amgen sued the state over the Prescription Drug Affordability Board’s decision to cap the price of Enbrel. The report says Amgen believes the law permitting the cap is unconstitutional and conflicts with federal law.
2024
Amgen sues Colorado over drug price board
Amgen filed a lawsuit against Colorado over the state Prescription Drug Affordability Board’s actions concerning Enbrel, arguing that the board’s actions are unconstitutional and seeking to overturn decisions about the drug and strike down parts of the law establishing the board.
2024
Amgen sues Colorado drug affordability board
Amgen and two subsidiaries filed a lawsuit in U.S. District Court in Denver alleging that the Colorado law creating the Prescription Drug Affordability Board is unconstitutional and should be overturned. The suit challenges the board's finding that Enbrel is unaffordable.
2023
FDA approves Amgen's WEZLANA
On October 31, the FDA approved Amgen's WEZLANA as a biosimilar to and interchangeable with Janssen's STELARA. The article identifies WEZLANA as the first product approved as a biosimilar to STELARA.
2023
Amgen completes acquisition of Horizon Therapeutics
Amgen announced that it completed its acquisition of Horizon Therapeutics for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
2023
Generate:Biomedicines raises $273 million in Series C financing
Generate:Biomedicines announced that it raised $273 million in Series C financing. The company said it would use the funds to advance its pipeline and validate and improve its AI platform.
2023
FTC sues to block Amgen's acquisition of Horizon Therapeutics
The U.S. Federal Trade Commission filed a lawsuit to stop Amgen's proposed $27.8 billion acquisition of Horizon Therapeutics. The FTC said it was concerned Amgen could use its leading drugs to pressure insurers and pharmacy benefit managers to grant favorable terms for Horizon products. Amgen said it was disappointed and disputed that the deal raised legitimate competitive issues.
2023
Amgen sues Sandoz and Novartis over proposed biosimilars
Amgen sued Novartis's Sandoz in New Jersey federal court, accusing Sandoz's proposed biosimilars of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire; the allegations are not presented as a court determination.
2023
Amgen sues Novartis and Sandoz over proposed biosimilars
Amgen sued Novartis and its Sandoz business in federal court in New Jersey, accusing Sandoz's proposed versions of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire.
2022
Amgen announces acquisition of Horizon Therapeutics
Amgen announced that it would acquire Horizon Therapeutics in a transaction valued at approximately $26.4 billion.
2022
Amgen Thailand earns Great Place to Work certification
Amgen Thailand announced that it received Great Place to Work certification for 2022–2023 following an independent audit.
2022
Inversago Pharma completes Series C financing
Inversago Pharma announced completion of a CAD 95 million Series C financing led by New Enterprise Associates, with additional new investors Forbion Growth Opportunities Fund and Amgen Ventures joining existing investors.
2022
Amgen agrees to acquire ChemoCentryx
Amgen announced an agreement to acquire ChemoCentryx in a cash transaction valued at approximately $3.7 billion, including the acquisition of ChemoCentryx's Tavneos treatment. The transaction was subject to customary closing conditions, stockholder approval and regulatory approvals, and was expected to close in the fourth quarter of 2022.
2022
IDEAYA and Amgen enter clinical trial collaboration
IDEAYA announced a clinical trial collaboration and supply agreement with Amgen to evaluate IDE397 in combination with Amgen's AMG 193 in a Phase 1 clinical trial. Amgen will sponsor the trial, and the companies will share external costs and jointly oversee development of the combination therapy.
2022
FDA approves RIABNI for rheumatoid arthritis
Amgen announced that the FDA approved RIABNI, in combination with methotrexate, for adults with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more tumor necrosis factor antagonist therapies.
2022
Amgen named recipient of LUNGevity Hope Award for Corporate Leadership
LUNGevity Foundation announced Amgen as the recipient of its 2022 Hope Award for Corporate Leadership. The award is scheduled to be presented at LUNGevity's annual NY Celebration of Hope Gala in November.
2022
Lindis Biotech sues Amgen over patents
Lindis Biotech filed a complaint against Amgen in the District of Delaware, alleging that Amgen infringed three patents relating to an immunotherapy regimen. The complaint seeks a declaration of infringement and damages, among other relief; the allegations are not presented as a court determination.
2021
FDA approves Tezspire for severe asthma
The U.S. Food and Drug Administration approved Tezspire, developed by Amgen and AstraZeneca, as add-on maintenance treatment for adult and pediatric patients aged 12 years and older with severe asthma.